News Release

Mortality and morbidity among individuals with hypertension receiving a diuretic, ace inhibitor, or calcium channel blocker

JAMA Network Open

Peer-Reviewed Publication

JAMA Network

About The Study: In this prespecified secondary analysis of outcomes of 32,000 participants in a randomized clinical trial and post-trial up to 23 years later among adults with hypertension and coronary heart disease risk factors, cardiovascular disease mortality was similar between all three antihypertensive treatment groups (thiazide-type diuretic, calcium channel blocker, or angiotensin-converting enzyme [ACE] inhibitor). ACE inhibitors increased the risk of stroke outcomes by 11% compared with diuretics, and this effect persisted well beyond the trial period. 

Authors: Jose-Miguel Yamal, Ph.D., of the University of Texas Health Science Center at Houston, is the corresponding author. 

 To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2023.44998)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.44998?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=120423


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.